Luye Pharma Group logo
2186 logo

Luye Pharma GroupSZSC:2186 Stock Report

Market Cap HK$8.8b
Share Price
n/a
1Y-19.3%
7D-2.1%
Portfolio Value
​
View

Luye Pharma Group Ltd.

SZSC:2186 Stock Report

Market Cap: HK$8.8b

2186 Stock Overview

An investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. More details

2186 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance4/6
Financial Health4/6
Dividends0/6

Rewards

Earnings are forecast to grow 14.36% per year

Earnings grew by 68.3% over the past year

Risk Analysis

No risks detected for 2186 from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Luye Pharma Group Ltd. Competitors

Shandong Xinhua Pharmaceutical

SEHK:719

HK$8.9b

SSY Group

SEHK:2005

HK$9.3b

China Traditional Chinese Medicine Holdings

SEHK:570

HK$9.8b

Beijing Tong Ren Tang Chinese Medicine

SEHK:3613

HK$6.7b

Price History & Performance

Summary of share price highs, lows and changes for Luye Pharma Group
Historical stock prices
Current Share PriceHK$2.34
52 Week HighHK$3.75
52 Week LowHK$1.97
Beta0.84
1 Month Change12.50%
3 Month Change-7.14%
1 Year Change-19.31%
3 Year Change-25.71%
5 Year Change-51.55%
Change since IPO-53.29%

Recent News & Updates

Recent updates

Shareholder Returns

2186HK PharmaceuticalsHK Market
7D-2.1%-4.3%-2.3%
1Y-19.3%0.8%25.0%

Return vs Industry: 2186 underperformed the Hong Kong Pharmaceuticals industry which returned 0.8% over the past year.

Return vs Market: 2186 underperformed the Hong Kong Market which returned 25% over the past year.

Price Volatility

Is 2186's price volatile compared to industry and market?
2186 volatility
2186 Average Weekly Movement4.4%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement6.7%
10% most volatile stocks in HK Market14.1%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 2186 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2186's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19945,234Dian Bo Liuwww.luye.cn

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Apleek Transdermal Patch for contraception; Rivastigmine Transdermal Patch for the treatment of Alzheimer’s disease; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders.

Luye Pharma Group Ltd. Fundamentals Summary

How do Luye Pharma Group's earnings and revenue compare to its market cap?
2186 fundamental statistics
Market capHK$8.80b
Earnings (TTM)HK$822.72m
Revenue (TTM)HK$6.74b

10.7x

P/E Ratio

1.3x

P/S Ratio

Is 2186 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2186 income statement (TTM)
RevenueCN¥6.31b
Cost of RevenueCN¥1.97b
Gross ProfitCN¥4.34b
Other ExpensesCN¥3.57b
EarningsCN¥770.46m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.20
Gross Margin68.73%
Net Profit Margin12.20%
Debt/Equity Ratio66.6%

How did 2186 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/01 13:23
End of Day Share Price 2025/02/28 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Luye Pharma Group Ltd. is covered by 21 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Jessica LiBofA Global Research
Lok Kwan ChiuCCB International Securities Limited